dvm3602d
Treatment options for moderate and severe atopic dermatitis, and when to use what
Jason B. Pieper, DVM, MS, DACVD, talks about the multiple therapies available for cases of moderate and severe atopic dermatitis and delves into each option ...
dvm36013d
Treatment options for mild atopic dermatitis
Jason B. Pieper, DVM, MS, DACVD: …It is tough when we talk about atopic dermatitis, I mean, there's a variety [of causes].
Medscape21d
Atopic Dermatitis News
2025 Stress Linked to Atopic Dermatitis Activity in Children Experiencing stressful life events in childhood was associated with an increased risk for active and severe atopic dermatitis ...
Monthly Prescribing Reference10d
Rezpegaldesleukin Fast Tracked for Moderate to Severe Atopic Dermatitis
Rezpegaldesleukin is currently being investigated in the phase 2b REZOLVE-AD study (ClinicalTrials.gov Identifier: NCT06136741) in 398 adult patients with moderate to severe atopic dermatitis who ...
Morningstar5d
Galderma’s Nemluvio® (Nemolizumab) Approved in the European Union for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis
Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is ...
Yahoo Finance9d
Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis
In patients with moderate-to-severe atopic dermatitis, rezpegaldesleukin has been shown to rapidly improve measurable exploratory disease outcomes during a 12-week induction treatment phase and ...
Mena FN5d
Galderma's Nemluvio® (Nemolizumab) Approved In The European Union For Moderate-To-Severe Atopic Dermatitis And Prurigo N...
(BUSINESS WIRE )--Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU).